Clinical Research: Participant Information Sheet, Consent Form, and Procedures

This clinical research study aims to compare the efficacy of Cognitive Behavior Therapy and Anti-Depressants in treating depression. The study involves a randomized control trial with 200 participants, who will be divided into two groups. The participant information sheet provides details on the purpose of the research, type of research intervention, participant selection, procedures, risks, benefits, and confidentiality. The consent form confirms the participant's voluntary participation in the study.

Clinical Research
Clinical Research
Name of the Student
Name of the University
Author Note

1Clinical Research
Contents
Participant Information Sheet:...................................................................................................3
Introduction:...........................................................................................................................3
Purpose of the research:.........................................................................................................3
Type of Research Intervention:..............................................................................................4
Participant Selection:.............................................................................................................4
Voluntary Participation:.........................................................................................................4
Information on Trial Drug......................................................................................................5
Procedures and Protocol:........................................................................................................5
A. Unfamiliar Procedures:.................................................................................................5
B. Description of the Process:............................................................................................6
Duration:................................................................................................................................6
Side Effects:...........................................................................................................................7
Risks:......................................................................................................................................7
Benefits:.................................................................................................................................7
Reimbursements:....................................................................................................................7
Confidentiality:......................................................................................................................7
Sharing the results:.................................................................................................................8
Right to refuse or withdraw:..................................................................................................8
Alternatives to participating:..................................................................................................8
Who to contact:......................................................................................................................8
Certificate of Consent:.............................................................................................................10

2Clinical Research
Consent Form...........................................................................................................................12
References:...............................................................................................................................14

3Clinical Research
Participant Information Sheet:
Introduction:
I am the lead researcher of a research team, working for _________. We are
conducting a Randomized Control Trial that is aimed to study and compare the efficacies of
two forms of treatment for depression, viz. Cognitive Behavior Therapy and administration of
Anti-Depressants. The trial will consist of 200 participants, and will continue for 3 months, to
analyse which treatment shows as being more effective. We would like you hereby invited to
participate in this study. Please note that you may contact me or anyone from the research
team if you have any questions regarding the research, and you can go through the details
provided in this information sheet to decide if you would like to participate in this. You do
not have to make your decision today whether you would like to participate, and your
correspondence is always welcome, if you have any doubts regarding the trial. There might
be certain technical aspects you might have difficulty understanding, in which care I you are
more than welcome to revert to me, and I shall try my best to explain it to you.
Purpose of the research:
Depression is a common mental health condition that affects more than 300 million
people from all age groups around the world. It is one of the leading causes of disability
globally and a major contributor to the overall burden of the disease (who.int, 2018).
Different treatments exists for depression such as psychological and pharmacological
interventions (Li, 2018). The aim of our study is to compare one psychological intervention
(Cognitive Behavior Therapy) with a pharmacological intervention (Anti-depressants) to find
out which strategy is more effective. Results from this trial can be used to inform clinical
decisions in the treatment of Depression.

4Clinical Research
Type of Research Intervention:
This research will involve a randomized control trial where the participants will be
divided into two groups. One group will be receiving Cognitive Behaviour Therapy and the
other group will be administered Anti Depressants (Selective Serotonin Reuptake Inhibitors).
The trial will last for 3 months, in which the participants will be administered either
antidepressants (regularly) or will undergo Cognitive Behaviour Therapy (in sessions). At the
end of the trial the participants will be re assessed for depressive symptoms to understand if
the effect of the treatments.
Participant Selection:
We are inviting all adults diagnosed with depression, and tested positive on PHQ 9
(which is a depression test questionnaire that is filled by the participants). The contacts were
collected from the General Physician referrals from the clinic ___________.
Voluntary Participation:
Kindly note that your participation in this trial is completely voluntary, and the
decision to participate in this or not is entirely yours. Also, the services available for you in
this clinic will remain unaffected by your decision whether you would like to participate or
not. If you do not wish to participate, you would receive the routine treatment offered in this
clinic, and we shall inform you more about the treatment in due course. You are also free to
change your decision to participate during the period of the trial, and withdraw from it at any
point of time. Also note that you do not have to take part in the trial, if you do not wish to. If
you have any questions, doubts, concerns or feedback or complaints about the trial, you can
get in touch with me or any member of the research team.

5Clinical Research
Information on Trial Drug
The trial drug being tested in this research is a Selective Serotonin Reuptake Inhibitor
(SRI) called Fluoxetine or Prozac, which is a commonly prescribed medicine for depression.
The medicine have been tested before with other antidepressants, however their efficacy have
not been tested against psychological therapy like Cognitive Behavior Therapy. This will be a
phase 3 trial.
Prozac is manufactured by Eli Lilly and Company, and can cause few side effects
such as nausea, stomach upset, headache, constipation, anxiety, drowsiness, insomnia,
nervousness, dizziness, heart palpitation, loss of appetite, symptoms of cold, impotency, loss
of sexual drive, and difficulty in having orgasms.
Half of the participants will be administered this medicine, while the other half will be
given placebo tablets.
Procedures and Protocol:
A. Unfamiliar Procedures:
1. Randomization and Blinding:
Since we do not know whether cognitive behavior therapy works better than Prozac,
we need to compare the two. In order to achieve this, we will divide the participants in 2
groups. The participants will be selected randomly in the two groups. Participants in group
one will be given Cognitive Behaviour therapy through counseling sessions that will focus to
improve the thought processes of the participants, and placebo medication, while the group
two will be administered Prozac. The trial will be single blinded, that is the participants will
be unaware of whether they are in group one or group two, however the research team will be
aware of it. At the end of the trial, all the participants will be debriefed.

6Clinical Research
2. Involving Drug and Placebo
The drug selected for the trial is Prozac, and a placebo that looks like Prozac tablets
(but contains sugar pills).
3. Rescue medication
If Prozac does not show the desirable effect, Sertaline or Zoloft will be used as a
rescue medication.
4. Treatment policy
You will receive treatment for depression according to the national guidelines, which
means you will undergo counseling and psychotherapy sessions with a psychologist and will
be given medications.
B. Description of the Process:
In the first visit, you will be asked to fill up a PHQ-9 form, which is a questionnaire. This will
help to understand the extent of the depressive symptoms experienced by you. After which
you will be assigned to one of the two groups. Based on the group, you will either undergoes
Cognitive Behaviour Therapy with a psychologist, who will help you to identify the
behavioural factors which causes depression, and help you to improve those thought
processes, and thus reduce depressive symptoms. Additionally placebo medications will be
provided. Alternatively you might also be given only Prozac (everyday). The trial will last for
3 months, at the end of which everyone will be asked to fill up the PHQ 9 questionnaire
again, to identify whether there have been any improvement in the condition among all
participants.
Duration:
The study will be conducted for 3 months.

7Clinical Research
Side Effects:
As previously informed, that some unwanted side effects might occur due to Prozac,
however the group receiving cognitive behavior therapy would be at no risk of adverse side
effects. Will closely monitor the onset of any side effects, and would also use additional
medications to reduce their risks. At all points we will keep you updated on the treatment,
and your participation will continue based upon your decision.
Risks:
The trial does not entail any risks for you. If Prozac or Cognitive Behavior Therapy
does not work, and your depressive symptoms persist after a week of treatment, you will
automatically be moved out of the trial and given alternative treatment, to ensure fastest
effect.
Benefits:
The benefit for participating in this trial is that your treatment will be covered for free,
and if you fall sick within the trial, its treatment will also be covered by us. Also through your
participation we might be able to discover whether Prozac is more effective than CBT, a
finding that can help the wider society.
Reimbursements:
We will provide you money for travelling and parking and also reimbursement for
lost work time. You will not be given any additional money or gifts for participation.
Confidentiality:
Identity of the participants will be kept confidential from the general public at all
points of time. Data from the research will also be confidential, and accessible only be the

8Clinical Research
research team. We will use numbers instead of names to identify the participants, thereby
ensuring confidentiality of records. Access to this data will be available only to the research
team and the sponsors.
Sharing the results:
The information gathered from the study will be regularly shared with you during the
meetings before it is shared with the public. Confidential and personal information will not be
shared. Crucial data will firse be dessiminated to all participants in meetings, after which it
will be shared with public.
Right to refuse or withdraw:
Participation in the trial is completely voluntary, and will not affect your treatment in
any manner. Even if you do not wish to participate, you will still get all the benefits from the
clinic that you would otherwise have. At any point of time, you can choose to stop
participating and that will not affect your rights as a patient in this clinic. Your treatment wil
remain unaffected.
Alternatives to participating:
If you do not wish to participate in the trial, you will be provided the standard
treatment that is practiced in this clinic.
Who to contact:
If you have any questions, you can ask any of the researchers or me now or at any
point of the study in the period of 3 months. You may contact any of the following personnel:
Sl no. Name Address Telephone Number Email
1
2

9Clinical Research
3
4
5
6
7
8
9
10

10Clinical Research
Certificate of Consent:
I have read the foregoing information, or it has been read to me. I have had the opportunity to
ask questions about it and any questions that I have asked have been answered to my
satisfaction. I consent voluntarily to participate as a participant in this research.
Print Name of Participant__________________
Signature of Participant ___________________
Date ___________________________
Day/month/year
Statement by the researcher/person taking consent
I have accurately read out the information sheet to the potential participant, and to the best of
my ability made sure that the participant understands that the following will be done:
1. Participants will be divided into two groups and provided treatment for depression: one
group will receive cognitive behavior therapy and the other group will revieve
pharmacotherapy (Prozac).
2. Selection in the two groups will be randomised
3. Placebo medication will be used, and the participants will not be aware if they are
receiving Prozac or placebo.
I confirm that the participant was given an opportunity to ask questions about the study, and
all the questions asked by the participant have been answered correctly and to the best of my

11Clinical Research
ability. I confirm that the individual has not been coerced into giving consent, and the consent
has been given freely and voluntarily.
A copy of this ICF has been provided to the participant.
Print Name of Researcher/person taking the consent________________________
Signature of Researcher /person taking the consent__________________________
Date ___________________________
Day/month/year
Centre Number:
Study Number:
Patient Identification Number for this trial:

12Clinical Research
Consent Form
Title of Project:
Name of Researche
Please initial all boxes
1. I confirm that I have read and understand the information sheet dated_____ for the
above study. I have had the opportunity to consider the information, ask questions and
have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw at any
time without giving any reason, without my medical care or legal rights being
affected.
3. I understand that relevant sections of my medical notes and data collected during the
study,may be looked at by individuals from [COMPANY NAME], from regulatory
authorities or from the NHS Trust, where it is relevant to my taking part in this
research. I give permission for theseindividuals to have access to my records.
4. I agree to my GP being informed of my participation in the study.
5. I agree to take part in the above study.

13Clinical Research
Name of Participant Date Signature
Name of Person Date Signature
taking consent.

14Clinical Research
References:
Li, J. (2018). Effect of Psychological Care Combined with Prozac on Patients with Post-
Stroke Depression. Journal of Nursing, 5(4), 1-3.
who.int (2018), Depression, retrieved on 13 June, 2018, from: http://www.who.int/news-
room/fact-sheets/detail/depression